Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study

Lee, Yin-Mei; Low, How Cheng; Lim, Lee Yong; Dan, Yock Young; Aung, Myat Oo; Cheng, Chee Leong; Wee, Aileen; Lim, Seng Gee; Ho, Khek Yu

doi:10.1016/j.gie.2012.05.023

Cited by 110 publications

(83 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Those individuals attaining a BMI reduction greater than 10% experience improvement in biochemical surrogate indices of NAFLD, IR, and NAS [254,255].…”

Section: Endoscopic Proceduresmentioning

confidence: 99%

The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Those individuals attaining a BMI reduction greater than 10% experience improvement in biochemical surrogate indices of NAFLD, IR, and NAS [254,255].…”

Section: Endoscopic Proceduresmentioning

confidence: 99%

The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans

et al. 2016

View full text Add to dashboard Cite

show abstract

“…[71 72] Lee et al evaluated the impact of intra-gastric balloon compared to placebo on liver histology. [73] Eighteen patients were randomized to either intra-gastric balloon placement plus diet and exercise or diet and exercise alone for 6 months. Patients who underwent balloon placement experienced a significant decrease in BMI compared to placebo (1.52 vs 0.8, P=0.0008) and had a significant improvement in NAS when compared to control patients (2 vs. 4, P=0.03).…”

Section: Aerobic Vs Resistance Trainingmentioning

confidence: 99%

Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis

Corey

Rinella

2016

Dig Dis Sci

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in the United States with a growing prevalence worldwide. Nonalcoholic steatohepatitis (NASH), progressive form of NAFLD can lead to the development of cirrhosis, hepatocellular carcinoma (HCC), and the need for liver transplantation. Treatment of NASH may decrease the risk of progressive disease. Treatment for NAFLD should center around weight loss and exercise. Pharmacotherapy with vitamin E and pioglitazone should be considered for those with NASH, especially those with fibrosis. Weight loss surgery is also an effective treatment for NASH in individuals with other indications for surgery. In this review we will discuss the currently available therapies for NASH including lifestyle, pharmacologic and surgical options.

show abstract

“…A study reported a decrease in the proportion of patients with the metabolic syndrome at the time of Orbera balloon removal from 42.9 to 15.1% (P < 0.0005) [28]. Additionally, weight loss as a result of IGB placement has resulted in significant improvement in patients with obstructive sleep apnea and nonalcoholic fatty liver disease [29,30].…”

Section: Intragastric Balloonmentioning

confidence: 99%